Washington's Attorney General Nick Brown has united with 19 other attorneys general in a collective affirmation of mifepristone's safety and the importance of maintaining access to this medical abortion drug. In a statement, Brown and his colleagues emphasized their commitment to upholding reproductive rights, a stance that directly counters recent calls from some Republican counterparts to limit or remove mifepristone from the market.
The controversy was sparked after these Republican state attorneys general petitioned the U.S. Food and Drug Administration (FDA) to reconsider the drug's availability, a move which was quickly met by a scientifically grounded defense of mifepristone from the 20 attorneys general. "The decision to reexamine access to this medication was made in response to a scientifically baseless letter and ignores decades of research that proves mifepristone is safe and effective," the coalition argued, according to a statement obtained by the office of the Washington Attorney General. They continued, asserting that medical decisions "should be left between patients, their families, and their providers—and they should be guided by science, not political agendas."
This isn't the first time Brown has stood in defense of mifepristone. In August, he was part of a multistate group urging the FDA to lift what they consider to be unwarranted constraints on the drug. They backed their position with substantial evidence reflecting the safety of medication abortion within their jurisdictions.
Statistics provided by the Washington State Department of Health reveal that medication abortions are overwhelmingly safe. Out of nearly 30,000 instances recorded in Washington in 2023 and 2024, less than 0.2% resulted in complications serious enough to require hospitalization. These figures seem to strongly back the coalition's stance, with arguably well-demonstrated support that both mifepristone and misoprostol have been used safely by over 7.5 million women in the U.S. for either abortion care or miscarriage management since FDA approval in 2000. The attorneys general from states including Arizona, California, and New York, among others, have rallied behind Brown in this assertion of the indispensable nature of reproductive health care access.
The response from the bipartisan coalition led by Brown serves to firmly root the contentious debate over mifepristone within the bounds of scientific discourse rather than political maneuvering. As the situation continues to develop, the coalition stands ready to actively safeguard access to essential reproductive care.
